Metrics to compare | LIPO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLIPOPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −3.2x | −0.5x | |
PEG Ratio | 0.00 | 0.12 | 0.00 | |
Price/Book | 0.1x | 2.3x | 2.6x | |
Price / LTM Sales | 0.2x | 126.2x | 3.2x | |
Upside (Analyst Target) | - | 111.6% | 48.1% | |
Fair Value Upside | Unlock | 1.8% | 6.6% | Unlock |
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. On March 30, 2026, Lipella Pharmaceuticals Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Western District of Pennsylvania.